Terms: = Colorectal cancer AND NFIB, RP11-280O24_2, 4781, ENSG00000147862, NFIB2, NFI-RED, NFIB3 AND Treatment
26954 results:
1. Upregulation of Immune checkpoint PD-L1 in Colon cancer cell lines and activation of T cells by Leuconostoc mesenteroides.
Altves S; Guclu E; Yetisgin E; Bilecen K; Vural H
World J Microbiol Biotechnol; 2024 May; 40(7):204. PubMed ID: 38755413
[TBL] [Abstract] [Full Text] [Related]
2. Second Chance for Cure: Stereotactic Ablative Radiotherapy in Oligometastatic Disease.
Salim N; Tumanova K; Popodko A; Libson E
JCO Glob Oncol; 2024 May; 10():e2300275. PubMed ID: 38754052
[TBL] [Abstract] [Full Text] [Related]
3. Clinicopathologic Profile and treatment Outcomes of colorectal cancer in Young Adults: A Multicenter Study From India.
Sehrawat A; Khanna M; Kayal S; Sundriyal D; Tiwari S; Cyriac S; Ravishankaran P; Raphael J; Mathew D; Panda SS; Moharana L; Mohanty SS; Mohanty SS; Philips A; Jain D; Jeyaraj P; David PH; Patil J; Saju SV; Rathnam K; Sharma N; Dheva K; Jinkala SR; Raja K; Penumadu P; Ganesan P
JCO Glob Oncol; 2024 May; 10():e2300225. PubMed ID: 38754051
[TBL] [Abstract] [Full Text] [Related]
4. Gene mutation profiling in microsatellite instability colorectal cancer and its association with the efficacy of immunotherapy: A retrospective study.
Liu Y; Cui K; Ma W
Cancer Med; 2024 May; 13(9):e6910. PubMed ID: 38746969
[TBL] [Abstract] [Full Text] [Related]
5. Quality of Life in Patients Undergoing Emergency Surgery for Complex colorectal cancer: Protocol and Piloting of the Surgical Utilization and Recovery Patterns for Advanced Stage colorectal cancer Study.
Ciubotaru C; Poenaru RC; Beuran M; Pătraşcu T; Turculeţ CȘ; Constantinescu G; Hostiuc S; Moldoveanu A; Negoi I
Chirurgia (Bucur); 2024 Apr; 119(2):156-170. PubMed ID: 38743829
[No Abstract] [Full Text] [Related]
6. An inflammation-related subtype classification for analyzing tumor microenvironment and clinical prognosis in colorectal cancer.
Pei J; Gao Y; Wu A
Front Immunol; 2024; 15():1369726. PubMed ID: 38742117
[TBL] [Abstract] [Full Text] [Related]
7. Projected estimates of cancer in Canada in 2024.
Brenner DR; Gillis J; Demers AA; Ellison LF; Billette JM; Zhang SX; Liu JL; Woods RR; Finley C; Fitzgerald N; Saint-Jacques N; Shack L; Turner D;
CMAJ; 2024 May; 196(18):E615-E623. PubMed ID: 38740416
[TBL] [Abstract] [Full Text] [Related]
8. Taking SCFAs produced by Lactobacillus reuteri orally reshapes gut microbiota and elicits antitumor responses.
Li N; Niu L; Liu Y; Wang Y; Su X; Xu C; Sun Z; Guo H; Gong J; Shen S
J Nanobiotechnology; 2024 May; 22(1):241. PubMed ID: 38735933
[TBL] [Abstract] [Full Text] [Related]
9. Examining variations in body composition among patients with colorectal cancer according to site and disease stage.
da Silva Nascimento ML; Alves Bennemann N; de Sousa IM; de Oliveira Bezerra MR; Villaça Chaves G; Moreira Lima Verde SM; Fernandes Maurício S; Barreto Campello Carvalheira J; Santos Mendes MC; Miranda AL; da Costa Pereira JP; Gonzalez MC; Prado CM; Fayh APT
Sci Rep; 2024 May; 14(1):10829. PubMed ID: 38734789
[TBL] [Abstract] [Full Text] [Related]
10. Analysis of risk characteristics for early progression and late progression in locally advanced rectal cancer patients: a large population-based and validated study.
Yu Y; Wu H; Qiu J; Wu S; Gan Y; Shao L; Lin C; Hong L; Wu J
Support Care Cancer; 2024 May; 32(6):340. PubMed ID: 38733415
[TBL] [Abstract] [Full Text] [Related]
11. Receptor Targeting Using Copolymer-Modified Gold Nanoparticles for pCMV-Luc Gene Delivery to Liver cancer Cells In Vitro.
Zenze M; Singh M
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732235
[TBL] [Abstract] [Full Text] [Related]
12. Distinct Driver Pathway Enrichments and a High Prevalence of
Tapia-Valladares C; Valenzuela G; González E; Maureira I; Toro J; Freire M; Sepúlveda-Hermosilla G; Ampuero D; Blanco A; Gallegos I; Morales F; Erices JI; Barajas O; Ahumada M; Contreras HR; González J; Armisén R; Marcelain K
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731914
[TBL] [Abstract] [Full Text] [Related]
13. An In Vitro Study on the Cytotoxic, Antioxidant, and Antimicrobial Properties of Yamogenin-A Plant Steroidal Saponin and Evaluation of Its Mechanism of Action in Gastric cancer Cells.
Stefanowicz-Hajduk J; Graczyk P; Hering A; Gucwa M; Nowak A; Hałasa R
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731847
[TBL] [Abstract] [Full Text] [Related]
14. Primary colon lymphomas: An analysis of our experience over the last 18 years.
Hasturk D; Akturk Esen S; Buyukaksoy M; Civelek B; Seven I; Uncu D
Medicine (Baltimore); 2024 May; 103(19):e38013. PubMed ID: 38728507
[TBL] [Abstract] [Full Text] [Related]
15. Efficacy of surgical treatment of perianal infection in patients with hematological malignancy.
He J; Ni Z; Li Z
Medicine (Baltimore); 2024 May; 103(19):e38082. PubMed ID: 38728504
[TBL] [Abstract] [Full Text] [Related]
16. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
Wang DS; Ren C; Li SS; Fong WP; Wu XJ; Xiao J; Li BK; Zheng Y; Ding PR; Chen G; Qiu MZ; Wang ZQ; Wang FH; Luo HY; Wang F; Wang XZ; Wang LY; Xie DJ; Chen T; Li LR; Lu ZH; Zhai XH; Liu TS; Yuan Y; Chen JQ; Tan Q; Pan ZZ; Wan DS; Zhang R; Yuan YF; Xu RH; Li YH
PLoS Med; 2024 May; 21(5):e1004389. PubMed ID: 38728364
[TBL] [Abstract] [Full Text] [Related]
17. Robotic transanal minimally invasive surgery (R-TAMIS): current evidence in the treatment of early rectal neoplasia.
O'Sullivan NJ; Temperley HC; Larkin J; McCormick JJ; Rausa E; McCormick P; Heriot A; Mehigan BJ; Warrier S; Kelly ME
Int J Colorectal Dis; 2024 May; 39(1):71. PubMed ID: 38724801
[TBL] [Abstract] [Full Text] [Related]
18. Malnutrition as an unfavorable prognostic factor after surgical treatment for metastatic colorectal cancer.
Skroński M; Olszewska N; Nyckowski P; Ukleja A; Lisowska J; Słodkowski M; Szczygieł B
Pol Przegl Chir; 2024 Mar; 96(3):1-8. PubMed ID: 38721641
[TBL] [Abstract] [Full Text] [Related]
19. IL-2RG as a possible immunotherapeutic target in CRC predicting poor prognosis and regulated by miR-7-5p and miR-26b-5p.
Gharib E; Rejali L; Piroozkhah M; Zonoobi E; Nasrabadi PN; Arabsorkhi Z; Baghdar K; Shams E; Sadeghi A; Kuppen PJK; Salehi Z; Nazemalhosseini-Mojarad E
J Transl Med; 2024 May; 22(1):439. PubMed ID: 38720389
[TBL] [Abstract] [Full Text] [Related]
20. Selective but not pan-CDK inhibition abrogates 5-FU-driven tissue factor upregulation in colon cancer.
Kayser A; Wolff A; Berlin P; Duehring L; Henze L; Mundkowski R; Bergmann W; Müller-Hilke B; Wagner C; Huehns M; Oehmcke-Hecht S; Maletzki C
Sci Rep; 2024 May; 14(1):10582. PubMed ID: 38719932
[TBL] [Abstract] [Full Text] [Related]
[Next]
